Products from BPS Bioscience
Sun, sea, and science: BPS Bioscience from San Diego, California promotes new scientific discoveries that lead to therapies by creating innovative solutions for research. BPS is an expert in recombinant proteins and enzymes, cell lines, virus-based tools, as well as biochemical and cellular assay systems. The high-quality products and services from BPS enable researchers worldwide to advance biological discoveries in a variety of disciplines, including epigenetics, cell signaling, SARS-CoV-2, immunotherapy, CRISPR, and adoptive cell therapies.
More information at: www.bpsbioscience.com
No results were found for the filter!
B2M Knockout A549 Cell line
Item number: BPS-82871
B2M Knockout A549 Cell Line is an A549 cell line where B2M (Beta-2-Microglobulin) has been genetically removed by CRISPR/Cas9 genome editing.
| Keywords: | CDABP0092, |
| Application: | B2M knock-down studies, T cell activation studies, antigen presentation, immune response |
| Species reactivity: | human |
5,948.00€
*
ADC Control Human IgG1-vcMMAE
Item number: BPS-82916-1
ADC Control Human IgG1-vcMMAE is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control, and the drug-linker conjugate for ADC is vcMMAE (HY-15575)1.
| Keywords: | Anti-Ig gamma-1 chain C region, Anti-Ig gamma-1 chain C region EU, Anti-Ig gamma-1 chain C region KOL, Anti-Ig gamma-1... |
| Application: | Cancer therapy target studies |
| Species reactivity: | human |
From 1,781.00€
*
ADC Control Human IgG1-vcMMAF
Item number: BPS-82917-1
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control, and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF1.
| Keywords: | Anti-Ig gamma-1 chain C region, Anti-Ig gamma-1 chain C region EU, Anti-Ig gamma-1 chain C region KOL, Anti-Ig gamma-1... |
| Application: | Cancer therapy target studies |
| Species reactivity: | human |
From 1,894.00€
*
Loncastuximab Tesirine
Item number: BPS-82918-1
Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse...
| Keywords: | Anti-CD19, Anti-B-lymphocyte antigen CD19, Anti-Differentiation antigen CD19, Anti-T-cell surface antigen Leu-12,... |
| Application: | Cancer therapy target studies |
| Species reactivity: | human |
| CAS | 1879918-31-6 |
| MW: | ~147 kD |
From 1,997.00€
*
Epratuzumab Tesirine
Item number: BPS-82919-1
Epratuzumab Tesirine (ADCT-602) is a novel CD22-targeted ADC. Epratuzumab Tesirine contains a PBD dimer and a payload SG32491.
| Keywords: | Anti-CD22, Anti-BL-CAM, Anti-SIGLEC2, Anti-Siglec-2, Anti-B-cell receptor CD22, Anti-T-cell surface antigen Leu-14,... |
| Application: | Cancer therapy target studies |
| Species reactivity: | human |
From 8,850.00€
*
Telisotuzumab Vedotin
Item number: BPS-82922-1
Telisotuzumab vedotin (ABBV-399) is an antibody-drug conjugate (ADCs) targeting c-Met. Telisotuzumab vedotin consists of Monomethyl Auristatin E (MMAE), Telisotuzumab antibody and a cleavable mc-val-cit-PABC type linker. Telisotuzumab vedotin can be used to study non-small cell lung cancer expressing c-Met protein1,2.
| Keywords: | Anti-MET, Anti-SF receptor, EC=2.7.10.1, Anti-HGF receptor, Anti-HGF/SF receptor, Anti-Proto-oncogene c-Met, Anti-Scatter... |
| Application: | Cancer therapy target studies |
| Species reactivity: | human |
| CAS | 1714088-51-3 |
| MW: | ~145 kD |
From 805.00€
*
Trastuzumab Emtansine
Item number: BPS-82923-1
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced...
| Keywords: | Anti-HER2, Anti-CD340, Anti-ERBB2, Anti-MLN 19, Anti-p185erbB2, EC=2.7.10.1, Anti-Proto-oncogene Neu, Anti-Proto-oncogene... |
| Application: | Cancer therapy target studies |
| Species reactivity: | human |
| CAS | 1018448-65-1 |
| MW: | ~148 kD |
From 1,915.00€
*
Farletuzumab Ecteribulin
Item number: BPS-82929-1
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0....
| Keywords: | Anti-FBP, Anti-FOLR, Anti-FOLR1, Anti-FR-alpha, Anti-KB cells FBP, Anti-Folate receptor 1, Anti-Folate receptor alpha,... |
| Application: | Cancer therapy target studies |
| Species reactivity: | human |
| CAS | 2407465-18-1 |
| MW: | ~149 kD |
From 2,761.00€
*
Cofetuzumab Pelidotin
Item number: BPS-82930-1
Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting ADC comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to...
| Keywords: | Anti-PTK7, Anti-CCK4, Anti-CCK-4, Anti-Colon carcinoma kinase 4, Anti-Protein-tyrosine kinase 7, Anti-Tyrosine-protein... |
| Application: | Cancer therapy target studies |
| Species reactivity: | human |
| CAS | 1869937-48-3 |
From 1,594.00€
*
SGN-B6A
Item number: BPS-82933-1
SGN-B6A is an ADC, which targets integrin beta-6 (ITGB6) through human IgG1 monoclonal antibody Sigvotatug, and exhibits cytotoxicity against multiple integrin beta-6-positive cancer cell through mitotic inhibitor MMAE1.
| Keywords: | Anti-ITGB6, Anti-Integrin beta-6, |
| Application: | Cancer therapy target studies |
| Species reactivity: | human |
From 2,069.00€
*
Tusamitamab Ravtansine
Item number: BPS-82934-1
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 , via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of...
| Keywords: | Anti-CEA, Anti-CD66e, Anti-Meconium antigen 100, Anti-Carcinoembryonic antigen, Anti-CEA cell adhesion molecule 5,... |
| Application: | Cancer therapy target studies |
| Species reactivity: | human |
| CAS | 2254086-60-5 |
From 2,253.00€
*
ORM-5029
Item number: BPS-82935-1
ORM-5029 is a first-in-class human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC) comprised of SMol006, a highly potent GSPT1 degrader, conjugated to Pertuzumab. ORM-5029 can be used for study of cancer1.
| Keywords: | Anti-HER2, Anti-CD340, Anti-ERBB2, Anti-MLN 19, Anti-p185erbB2, EC=2.7.10.1, Anti-Proto-oncogene Neu, Anti-Proto-oncogene... |
| Application: | Cancer therapy target studies |
| Species reactivity: | human |
From 3,072.00€
*
